MEG 21

MEG 21 with SupplamineŽ began as a tangent while researching new treatments for diabetes-related complications. While the research focused on treating and preventing kidney disease and blindness in diabetic patients, Dr. Annette M. Tobia, Ph.D., realized that, when topically applied, many of these same compounds used to treat diabetics could also be used to treat and prevent visible signs of aging in the skin. Dr. Tobia conducted seven independent trials before commercializing MEG 21 with SupplamineŽ. ANTI-GLYCATION SOLUTIONS

These innovative products revolve around the glycation theory, which suggests that glucose binds to proteins and lipids in the skin, causing oxidative stress and premature aging. MEG 21 with SupplamineŽ is designed to combat these effects, offering solutions that plump and firm fine lines and wrinkles, even skin tone, reduce redness, brighten dark spots, and improve texture.